Doxazosin Tablet
Product Images NDC 68071-4892

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 68071-4892). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 4892 9)

Doxazosin 4 mg tablets label from NuCare Pharmaceuticals, Inc. The label specifies a quantity of 90 tablets per package and describes each tablet as capsule-shaped, light pink to pink mottled, scored, and debossed with '785'. It includes NDC 68071-4892-9, product number P0377090, and storage instructions at controlled temperatures between 68-77°F. The label also features lot numbers, expiration date placeholders, and manufacturer details.*

FDA Label Image

Doxazosin Tablets, Usp (A308818e E36c 4431 Bf51 274650c38cb0 01)

Chemical structure of doxazosin, showing its molecular components and bonding arrangement. The structure includes aromatic rings, a piperazine ring, and functional groups characteristic of doxazosin mesylate.*

FDA Label Image

Doxazosin Tablets (A308818e E36c 4431 Bf51 274650c38cb0 02)

A data table comparing symptom score and maximum flow rate (mL/sec) in three studies of Doxazosin at various dosages versus placebo. The table shows mean baseline values and mean changes from baseline for symptom scores and maximum flow rate, indicating statistical significance where applicable. A bar graph on the right illustrates maximum flow rate changes in Study 2 for placebo, 4 mg, and 8 mg doses of Doxazosin, highlighting significant improvements compared to placebo.*

FDA Label Image

Doxazosin Tablets, Usp (A308818e E36c 4431 Bf51 274650c38cb0 03)

Two line graphs showing effects of Doxazosin versus placebo over a 14-week treatment period. The first graph depicts mean change in total symptom score from baseline, with Doxazosin showing a greater reduction than placebo. The second graph shows mean increase in maximum urinary flow rate (mL/sec) from baseline, where Doxazosin demonstrates higher improvement compared to placebo. Both graphs include sample sizes (Doxazosin N=50, placebo N=47) and error bars.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.